|
Press Releases |
|
|
|
Tuesday, April 16, 2024 |
|
中国抗体SM17治疗特应性皮炎(AD)之临床前结果刊登于国际科学期刊《Allergy》 |
more info >> |
|
中國抗體SM17治療特應性皮炎(AD)之臨床前結果刊登於國際科學期刊《Allergy》 |
more info >> |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
中国抗体SM17新药研究申请再获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗特应性皮炎(“AD”)的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”) more info >> |
|
中國抗體SM17新藥研究申請再獲國家藥監局批准 |
專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,本公司所提交之治療特應性皮炎(「AD」)的同類首創(First-in-Class)治療產品SM17的新藥研究申請(「新藥研究申請」) more info >> |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗哮喘的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”)于2023年8月11日获中国国家药品监督管理局(“国家药监局”)批准。 more info >> |
|
中國抗體SM17針對治療哮喘疾病的新藥研究申請獲國家藥監局批准 |
專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,本公司所提交之治療哮喘的同類首創(First-in-Class)治療產品SM17的新藥研究申請(「新藥研究申請」)於2023年8月11日獲中國國家藥品監督管理局(「國家藥監局」)批准。 more info >> |
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, June 12, 2023 |
|
中国抗体SM17再增一项适应症研究申请 针对治疗特应性皮炎(AD)的新药研究申请获国家药监局药品审评中心受理 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,SM17(注射用人源化抗IL-17RB单克隆抗体)针对治疗特应性皮炎(AD)的新药研究申请已于6月9日获中国国家药品监督管理局(“国家药监局”)药品审评中心受理。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Brawijaya University researcher develops honey-processing tech
Apr 19, 2024 23:00 HKT/SGT
|
|
|
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
Apr 19, 2024 21:45 HKT/SGT
|
|
|
UK's Largest EV Show Returns for 4th Edition Driving Innovation with Policy Leaders, Product Launches, and EV Innovations
Apr 19, 2024 21:03: JST
|
|
|
UK's Largest EV Show Returns for 4th Edition Driving Innovation with Policy Leaders, Product Launches, and EV Innovations
Apr 19, 2024 20:03 HKT/SGT
|
|
|
SMC Announces Marketing Agreement with Plato Technologies. Inc.
Apr 19, 2024 16:03 HKT/SGT
|
|
|
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
|
|
|
Prestigious titles for top developers at the 14th PropertyGuru Asia Property Awards (Singapore)
Apr 19, 2024 11:30 HKT/SGT
|
|
|
Revolutionizing Tomorrow: Uniting Visionaries at the 2024 Digital Transformation Summit Philippines
Apr 19, 2024 11:23 HKT/SGT
|
|
|
朝雲集團(06601.HK):穩健增長與高派息策略共驅,多家頭部券商給予增持評級
Apr 19, 2024 10:24 HKT/SGT
|
|
|
22nd Edition of Cyber Security Summit: Thailand to Convene Esteemed Panel of Industry Leaders
Apr 19, 2024 10:11 HKT/SGT
|
|
|
The Rapidly Evolving Real Estate Landscape: Redefine Real Estate Summit Connects Key Players in South East Asia
Apr 19, 2024 10:11 HKT/SGT
|
|
|
富士通、世界初 形式の異なる企業のデジタルアイデンティティー証明書を変換する技術を開発し欧州データスペースへの接続実証に成功
Apr 19, 2024 10:00: JST
|
|
|
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
|
|
|
Rapid Evolution in Philippines' BFSI Sector: BFSI IT Summit 2024 to Illuminate Transformation
Apr 19, 2024 08:02 HKT/SGT
|
|
|
GLOBE LIFE (GL): Kaplan Fox & Kilsheimer LLP Investigates GLOBE LIFE and Encourages Investors to Contact the Firm
Apr 19, 2024 08:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|